Investor FAQs

GENERAL/CORPORATE

PLx Pharma’s corporate headquarters are located at 8285 El Rio Suite 130, Houston, TX 77054.
PLx Pharma was incorporated in Delaware on July 27, 2015.
PLx Pharma became a public company upon the closing of the merger with Dipexium Pharmaceuticals, Inc. 
PLx Pharma’s fiscal year is from January 1 to December 31.
PLx Pharma’s stock is traded as common stock on the NASDAQ Capital Markets under the ticker symbol “PLXP”.

TRANSFER AGENT

The transfer agent and registrar for shares of PLx Pharma’s common stock is VStock Transfer, LLC. 
Contact PLx Pharma’s transfer agent, VStock Transfer: 

VStock Transfer, LLC
18 Lafayette Pl
Woodmere, NY 11598
Phone:  212-828-8436
Toll-Free: 855-9VSTOCK
Email: info@vstocktransfer.com
Website: https://www.vstocktransfer.com/
 
VStock Transfer is available to assist shareholders with stock transfers, changes of address, and replacement of lost stock certificates.

VStock Transfer, LLC
18 Lafayette Pl
Woodmere, NY 11598
Phone:  212-828-8436
Toll-Free: 855-9VSTOCK
Email: info@vstocktransfer.com
Website: https://www.vstocktransfer.com/
No, PLx Pharma does not have a direct stock purchase plan.

AUDITOR/LEGAL

PLx Pharma’s auditor is GBH CPAs, PC (Houston).
PLx Pharma’s legal counsel is Jackson Walker LLP (Dallas).

COMPANY INQUIRIES

All latest corporate news releases and financial reports can be found under “Investors” on PLx Pharma’s website under “New and Events”.
SEC filings can be found in the “Investors” section PLx Pharma’s website under “Financial Information".
Information on PLx Pharma’s Management team and Board of Directors can be found on our website: www.plxpharma.com in the “About Us” section under "Board of Directors" and “Management Team”.
To get more information or materials on PLx Pharma, please visit the “Contact Us” section of the website to fill out the form to request information via email.

You can also contact PLx Pharma Inc. at: 
Phone: (713) 842-1249
Fax: (713) 842-3052
Email: info@plxpharma.com
 
Please contact In-Site Communications with any investor inquiries.

In-Site Communications
Lisa Wilson
Email: lwilson@insitecony.com
Phone: 212.452.2793
 
You can sign up for email updates through PLx Pharma’s distribution list in the “E-mail Alerts” section of our website.